355results about "Fusions with soluble cell surface receptor" patented technology

In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.

Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathethic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawl, postpartum depression, and schizoaffective illness.

Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.

The invention relates to chimeric antigen receptors (CAR), particularly relates to dual-signal independent chimeric antigen receptors (dsCAR), and also relates to immune response cells of the dual-signal independent chimeric antigen receptors (dsCAR) and uses of the immune response cells in preparation of drugs for treatment of malignant tumor and virus infected diseases. In detail, the dual-signal independent chimeric antigen receptors (dsCAR) can respectively identify two different family antigens of tumor cells and can respectively transmit two T-cell-activation related signals. One of the CAR can transmit a first T-cell-activation related signal by combing a ligand of a tumor specific antigen or a tumor-associated antigen to decide T-cell killing specificity, and the other CAR can transmit a second T-cell-activation related signal by combing a ligand of a membrane receptor (such as EGFR (epidermal growth factor receptor) family protein) widely expressed by the tumor cells to promote T cell activation, proliferation and survival. The dual-signal independent chimeric antigen receptors (dsCAR) can avoid the potential safety problems on the basis of maintaining curative effects of second generation and third generation CAR.

This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.

The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can interact with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occupancy of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences.

The present invention relates to rapid clearance molecules that bind target antigens and FcγRIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.

The present invention provides compositions and methods for treating abnormal cell proliferation and for regulating angiogenesis. In particular, multivalent protein conjugates (MVPs) are constructed to include multiple ligand-binding domains of different receptors and utilized to target multiple, different ligands that are involved in regulation of cell growth and neovascularization. The MVPs of the present invention can be used to treat various conditions associated with abnormal cell proliferation and angiogenesis such as cancer and cardiovascular disorders, as well as to promote wound healing.

A method for producing viral gene delivery vehicles which can be transferred to pre-selected cell types by using targeting conjugates. The gene delivery vehicles comprise: 1) the gene of interest; and 2) a viral capsid or envelope carrying a member of a specific binding pair, the counterpart of which is not directly associated with the surface of the target cell. These vehicles can be rendered unable to bind to their natural cell receptor. The targeting conjugates include the counterpart member of the specific binding pair, linked to a targeting moiety which is a cell-type specific ligand (or fragments thereof). The number of the specific binding pair present on the viral vehicles can be, for example, an immunoglobulin binding moiety (e.g., capable of binding to a Fc fragment, protein A, protein G, FcR or an anti-Ig antibody), or biotin, avidin or streptavidin. The virus' outer membrane or capsid may contain a substance which mediates entrance of the gene delivery vehicle into the target cell. Due to the specificity of the ligand, the binding pair's high affinity, and the gene delivery vehicle's inability to be targeted when used alone, the universality of the method for gene delivery, together with its high cell type selectively can be achieved by using various targeting conjugates.

The invention relates to isolated fully human monoclonal antibodies having specificity for human NKG2D and compositions thereof. The invention further relates to methods for using such antibodies in treating diseases or conditions such as cancer, autoimmune disease, or infectious disease.

Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGFβ) antagonists are disclosed, where the agents and/or antagonists include a therapeutically effective amount of a combination of therapeutically active portions of sRII and therapeutically active portions of sRIII or a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII. Methods for preventing, treating and/or ameliorating the symptoms of cancer are also disclosed based on administering an effective amount of a composition of this invention.

Methods of reducing C-reactive protein (CRP) in a subject, comprising administering to the subject a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein CRP is reduced. The IL-1 antagonist is preferably an IL-1-binding fusion protein (IL-1 trap), preferably comprising SEQ ID NO:2.

The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an Fc³R, derivatives and analogs thereof, and nucleic acids encoding the same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.

Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR⁷ and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.

Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells.

In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide.

The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.

The resulting fusion peptide being exemplified as

• NH2-CD4-GBP130-COOH
• 1-371 201-774

Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection.

The invention relates to modulating the SIRPα-CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is provided isolated SIRPα and CD47 polypeptides, fragments and fusion proteins for enhancing hematopoietic stem cell engraftment. Further there is provided methods for increasing hematopoietic stem cell engraftment through administration of the above polypeptides.